GlaxoSmithKline : Another year of transition impacted by COVID-19
>Q4 cannot be extrapolated for this H1 - Whilst we had hoped that this year would mark the low point, the lack of visibility due to the pandemic and the investment in R&D have prompted the group to warn of another year of decline. The end of 2020, however, raises very few questions. Q4 was even of good quality, 1% below forecasts for the top line and 1% above for EPS anticipated. As we had anticipated, the “established drugs” and consumer activities were the hardest h...GlaxoSmithKline is a global healthcare company. Co.'s segments include: Pharmaceuticals; Vaccines; and Consumer Healthcare. The Pharmaceuticals segment is focused on developing new medicines in respiratory, HIV, oncology and immuno-inflammation, with discovery research exploring these and other areas. The Vaccines segment has a portfolio and pipeline of vaccines to help protect people throughout life. Co. delivers vaccines to people living in over 160 countries. The Consumer Healthcare segment develops and markets consumer-preferred brands in oral health, pain relief, respiratory, nutrition/gastro-intestinal and skin health.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.